By successfully turning the "cold” tumor into "hot” - transforming the tumor microenvironment from having low immune activity ...

Eterna Therapeutics, Inc. (ERNA) announced Tuesday positive results from a preclinical study on the company's lead cell therapy ...

Cells is under clinical development by ICamuno Biotherapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition ...

June 23, 2023 — Using 3-D models of ovarian cancer tumors, scientists found differences in gene activity based on where a cell is in a tumor, demonstrating how a cell's location and environment ...

ovarian, and endometrial cancer. MCLA-117 is a T cell engager designed to retarget T cells via CLEC12A—a first-in-class target expressed by acute myeloid leukemia (AML) blast and stem cells with ...

The modified stem cells are then reinfused back into the ... with other agents for the treatment of advanced refractory ovarian cancer and small cell lung cancer are currently underway.